Clinical Director of the CHOC Research Program, pediatric hematologist/oncologist Violet Shen, M.D. provides expertise in neuro-oncology and new-agent clinical trials. Dr. Shen is board certified in pediatrics and pediatric hematology/oncology. She served a fellowship at Memorial Sloan-Kettering Cancer Center in New York. She completed her residency and internship at Cornell Medical College, North Shore University Hospital in Manhasset and at St. Vincent's Hospital and Medical Center in New York City, respectively. Dr. Shen received her medical training at National Taiwan University in Taipei. She also speaks Chinese. Dr. Shen manages the Neuro Oncology Clinic at CHOC.
Dr. Shen is leading the way for CHOC’s cancer research as the principal investigator for the Children’s Oncology Group (COG) studies, the Children’s Cancer Group (CCG) phase I research, and the COG phase I consortium. CHOC Children's Cancer Institute has been designated as a Phase I clinical trial facility by the Children’s Oncology Group (COG), the nation’s predominant clinical trials group for children and young adult patients with cancer. The Cancer Institute is the only hospital in the southwestern United States—and one of only 21 in North America—offering children Phase I clinical trials for new drugs or treatment. This distinction has provided hope for children whose cancers don’t respond to standard treatment and has made it possible for Dr. Shen and her colleagues to have more than 80 open studies.
Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll WL. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009 Dec;23(12):2259-64. Epub 2009 Sep 10.
Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006 Apr 20;24(12):1917-23.
Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, Camitta B, Pui CH. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005 Jan;19(1):34-8.
Shen V, Li X, Murdock M, Resnansky L, McCluskey E, Semba C: Recombinant tissue plasminogen activator (Alteplase) for restoration of function to occluded central venous catheters in pediatric patients. J Pediatr Hematol Oncol 25: 38-45, 2003
Marcos Di Pinto, Ph.D., Violet Shen, M.D., Laura McDonald, M.S., Grace Mucci, Ph.D., Julene Schenk, RN,BSN, Tina Templeman RN, Jody Pathare NP, Kristin Hawking : Intellectual Outcome in Bilingual and Monolingual Children with Medulloblastoma , to be presented at the International Symposium on Pediatric Neuro-Oncology (ISPNO), Vienna, Austria.
Van Huynh, Tina Templeman, Violet Shen, “Toxicity profile of Bevacizumab based regimens in the treatment of pediatric malignant brain tumors - a Single Institution’s Experience, to be presented at International Symposium on Pediatric Neuro-Oncology (ISPNO), Vienna, Austria.
A Lee1, C Fanelli1, LA Harrison1, V Shen2, L Gates2, R Wells2, JE Wolff3, JH Garvin1, DJ Yamashiro1,5, MS Cairo1,4,5 Pilot study of the novel chemotherapy regimen of Topotecan, Ifosfamide, and Carboplatin (TIC) in Children with Refractory/Recurrent Solid Tumors, to be presented at the American Society of Clinical Oncology 2010 Meeting.
Nobuko Hijiya, Paul Gaynon, Manuel Fernandez, Lewis Silverman, Blythe Thomson, Roland Chu, Todd Cooper, Richard Kadota, Michael Rytting, Peter Steinherz, Violet Shen, Sima Jeha, Elly Barry, William L. Carroll: Durable Remissions Observed in a Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemia. (presented at ASH 2008)
Kadota R, Shen V, Messinger Y: Safety, pharmacokinetics and efficacy of palonosetron in pediatric patients: A multicenter, stratified, double-blind, phase 3, randomized study. Am Soc Clin Oncol 25: No 18S 543s, 2007
Jeha S, Razzouk, M, Rytting M, Gaynon P, Kadoto R, Rheingold S, Luchtman-Jones L, Shen V, Arceci R, Fernandez M, Weitman S, Steinherz P: Phase II trials of Clofarabine in relapsed or refractory pediatric leukemia. Blood 104 (11):196a, 2004
Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, Camitta B, Pui CH: Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005 Jan;19(1):34-8.
Cairo MS, Davenport V, Bessmertny O, Goldman SC, Berg SL, Kreissman SG, Laver J, Shen V, Secola R, van de Ven C, Reaman GH: Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br. J Haematol 128(1):49-58, 2005
Sima Jeha, Bassem Razzouk, Michael Rytting, Paul Gaynon, Richard Kadota, Susan Rheingold, Lori Luchtman-Jones, Violet Shen, Robert Arcecci. Manuel Fernandez, Steve Weitman, Peter Steinherz: Phase II trials of Clofarabine in relapsed or refractory pediatric leukemia. Blood 104, No 11: 196A,2004
Anderson, P/M., Meyers, P, Kleinerman E, Venkatakrishnan, Hughes, D.P, Herzog C, Huh W, Sutphin R, Vyas YM, Shen, V, Warwick A, Yeager N, Oliva C, Wang B, Liu Y, Chou A: Mifamurtide in Metastatic and Recurrent Osteosarcoma: A Patient Access Study with Pharmacokinetic, Pharmacodynamic and Safety Assessments. Pediat r Blood Cancer, Published online in Wiley Online Library 2013
Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper, T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll W: A multi-center phase 1 study of Clofarabine, Etoposide and Cyclophosphamide in combination in pediatric p atients with refractory or relapsed acute leukemia. Blood 118:6043-6049, 2011
N Hijiya, P Gaynon, E Barry, L Silverman, B Thomson, R Chu, T Cooper, R Kadota, M Rytting, P Steinherz,V Shen, S Jeha, R Abichandan and WL Carroll: A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia 23, 2259–2264,2009
CHOC Children's Specialists
1201 W La Veta
Orange, CA 92868
phone: (714) 509-8636
fax: (714) 509-4748
map & directions